Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Operations: 2011-2025

Historic Cash from Operations for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $13.3 million.

  • Adma Biologics' Cash from Operations fell 46.89% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 24.50%. This contributed to the annual value of $118.7 million for FY2024, which is 1248.55% up from last year.
  • As of Q3 2025, Adma Biologics' Cash from Operations stood at $13.3 million, which was down 37.12% from $21.1 million recorded in Q2 2025.
  • Adma Biologics' Cash from Operations' 5-year high stood at $50.2 million during Q4 2024, with a 5-year trough of -$33.5 million in Q4 2021.
  • Its 3-year average for Cash from Operations is $12.9 million, with a median of $13.3 million in 2025.
  • Per our database at Business Quant, Adma Biologics' Cash from Operations surged by 853.36% in 2024 and then slumped by 787.06% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Cash from Operations stood at -$33.5 million in 2021, then surged by 77.95% to -$7.4 million in 2022, then soared by 338.47% to $17.6 million in 2023, then spiked by 185.37% to $50.2 million in 2024, then tumbled by 46.89% to $13.3 million in 2025.
  • Its Cash from Operations was $13.3 million in Q3 2025, compared to $21.1 million in Q2 2025 and -$19.7 million in Q1 2025.